SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with
sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.